General Information of DTT (ID: TTQVOEI)

DTT Name Angiotensin II receptor type-2 (AGTR2) DTT Info
Gene Name AGTR2

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
2 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
ANGIOTENSIN II DMLWQ27 Increase blood pressure BA04 Approved [1]
SARALASIN DMKS1DV Hypertension BA00-BA04 Approved [2]
------------------------------------------------------------------------------------
2 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
EMA-401 DMYOUB6 Peripheral neuropathy 8C0Z Phase 2 [3]
MP-157 DM5VXWO Hypertension BA00-BA04 Phase 1 [4]
------------------------------------------------------------------------------------
3 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1 DMGYZQ2 N. A. N. A. Patented [5]
Phenylpyridine derivative 3 DMDT5JI N. A. N. A. Patented [5]
PMID25416646-Compound-Figure5-E DMYO7VH N. A. N. A. Patented [5]
------------------------------------------------------------------------------------
9 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fonsartan DM15LAP Hypertension BA00-BA04 Discontinued in Phase 2 [6]
L-158282 DMKSEIY N. A. N. A. Discontinued in Phase 2 [7]
TAK-591 DM25DB4 Hypertension BA00-BA04 Discontinued in Phase 1 [8]
L-158809 DMQ4LDB Hypertension BA00-BA04 Terminated [7]
L-159689 DM9JE7Y Hypertension BA00-BA04 Terminated [9]
L-162234 DMYSEBK N. A. N. A. Terminated [10]
PD-123319 DM92VUF N. A. N. A. Terminated [11]
SC-50560 DM8UDSF N. A. N. A. Terminated [12]
SC-51895 DMWO107 N. A. N. A. Terminated [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Discontinued Drug(s)
11 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
angiotensin III DMYK0Z9 Discovery agent N.A. Investigative [13]
L-159093 DMOX8JE Discovery agent N.A. Investigative [14]
L-162313 DMZOW96 Discovery agent N.A. Investigative [15]
PD123177 DM4OQZX Discovery agent N.A. Investigative [16]
PMID22802221C21 DMVK1GT Discovery agent N.A. Investigative [17]
Sar-Arg-Val-Tyr-Ile-His-Pro-Ala DMCNOJV Discovery agent N.A. Investigative [11]
Sar-Arg-Val-Tyr-Ile-His-Pro-Ile DMS0FQC Discovery agent N.A. Investigative [11]
Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH DMD6SJT Discovery agent N.A. Investigative [18]
SC-52892 DMXA6LU Discovery agent N.A. Investigative [12]
SC-55634 DMLJ8T7 Discovery agent N.A. Investigative [12]
[125I]CGP42112 DM1NXDA Discovery agent N.A. Investigative [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Investigative Drug(s)
Molecule Interaction Atlas

References

1 The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists, Bioorg. Med. Chem. Lett. 3(5):895-898 (1993).
2 cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
3 Clinical pipeline report, company report or official report of Spinifex.
4 As drug target reemerges, the question is to block or stimulate it. Nature Medicine. Spoonful of Medicine. 05 Feb 2014. Cassandra Willyard
5 PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
6 Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens. 1998 Dec;16(12 Pt 2):2039-43.
7 Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors, Bioorg. Med. Chem. Lett. 4(1):189-194 (1994).
8 Clinical pipeline report, company report or official report of Takeda (2009).
9 The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT1 and AT2 receptor antagonists, Bioorg. Med. Chem. Lett. 6(8):923-928 (1996).
10 Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity. J Med Chem. 2000 May 18;43(10):1993-2006.
11 Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 sub... J Med Chem. 1991 Nov;34(11):3248-60.
12 N1-sterically hindered 2H-imidazol-2-one angiotensin II receptor antagonists: The conversion of surmountable antagonists to insurmountable antagonists, Bioorg. Med. Chem. Lett. 3(6):1055-1060 (1993).
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 35).
14 A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor. J Med Chem. 1993 Oct 15;36(21):3207-10.
15 Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition. Bioorg Med Chem. 2010 Jun 15;18(12):4570-90.
16 Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands. Mol Pharmacol. 1990 Mar;37(3):347-51.
17 Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism. Hypertension. 2012 Sep;60(3):722-9.
18 1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem. 1991 Apr;34(4):1514-7.
19 Radioiodinated CGP 42112A: a novel high affinity and highly selective ligand for the characterization of angiotensin AT2 receptors. Biochem Biophys Res Commun. 1991 Dec 31;181(3):1365-71.